Antibody responses within two leading Plasmodium vivax vaccine candidate antigens in three geographically diverse malaria-endemic regions of India
Antibody responses within two leading Plasmodium vivax vaccine candidate antigens in three geographically diverse malaria-endemic regions of India
复制标题
DOI：
10.1186/s12936-019-3066-6
复制
发表时间：
2019-12-16
期刊：
影响因子：
3
通讯作者：
Mallick, Prashant K.
中科院分区：
文献类型：
--
作者：
Kale, Sonal;Yadav, Chander P.;Mallick, Prashant K.
工作背景：在不同的生态流行病学环境中，寻找具有高度免疫原性的血液阶段抗原作为自然获得抗体的靶标是疟疾疫苗设计的重要步骤。间日疟原虫的血液期蛋白、顶端膜抗原-1（PvAMA-1）和裂殖子表面蛋白的19 kDa片段（PvMSP-1（19））是这样的有希望的疫苗候选抗原。本研究确定了自然获得的抗体反应PvAMA-1和PvMSP-1（19）抗原的个人生活在三个地理上不同的疟疾流行regionsofIndia.Methods：共收集了234份血液样本的个人生活在三个不同的生态流行病学设置，钦奈，纳迪亚德，和印度的鲁尔克拉。进行间接ELISA以测量针对重组PvAMA-1和PvMSP-1（19）抗原的人IgG抗体。结果：PvAMA-1和PvMSP-1的总血清阳性率分别为40.6%和62.4%（19）。钦奈（47%）的PvAMA-1血清阳性率较高，其次是纳迪亚德（46.7%）和鲁尔克拉（27.6%）。对于PvMSP-1（19），钦奈（80.3%）的血清阳性率高于Nadiad（53.3%）和鲁尔克拉（57.9%）。在钦奈，两种抗原的血清阳性率较高，其中间日疟原虫是主要的疟疾物种。此外，在每个研究中心观察到PvAMA-1和PvMSP-1（19）抗原的异质性抗体应答。两个因素，年龄和疟疾阳性与抗原PvAMA-1和PvMSP-1的血清阳性显著相关（19）。结论：这些数据表明，在印度三个地理上不同的疟疾流行区，与PvAMA-1抗原相比，PvMSP-1（19）抗原的自然获得性抗体应答更高。PvMSP-1（19）似乎在印度人群中具有高度免疫原性，并且具有作为疟疾疫苗候选物的巨大潜力。针对疫苗候选抗原的免疫应答在不同流行环境中的差异应被考虑用于开发基于无性生殖阶段的间日疟原虫疟疾疫苗，这反过来可以增强疟疾控制工作。
Background: Identifying highly immunogenic blood stage antigens which can work as target for naturally acquired antibodies in different eco-epidemiological settings is an important step for designing malaria vaccine. Blood stage proteins of Plasmodium vivax, apical membrane antigen-1 (PvAMA-1) and 19 kDa fragment of merozoite surface protein (PvMSP-1(19)) are such promising vaccine candidate antigens. This study determined the naturally-acquired antibody response to PvAMA-1 and PvMSP-1(19) antigens in individuals living in three geographically diverse malaria endemic regions of India.Methods: A total of 234 blood samples were collected from individuals living in three different eco-epidemiological settings, Chennai, Nadiad, and Rourkela of India. Indirect ELISA was performed to measure human IgG antibodies against recombinant PvAMA-1 and PvMSP-1(19) antigens. The difference in seroprevalence and factors associated with antibody responses at each site was statistically analysed.Results: The overall seroprevalence was 40.6% for PvAMA-1 and 62.4% for PvMSP-1(19). Seroprevalence to PvAMA-1 was higher in Chennai (47%) followed by Nadiad (46.7%) and Rourkela (27.6%). For PvMSP-1(19), seroprevalence was higher in Chennai (80.3%) as compared to Nadiad (53.3%) and Rourkela (57.9%). Seroprevalence for both the antigens were found to be higher in Chennai where P. vivax is the dominant malaria species. In addition, heterogeneous antibody response was observed for PvAMA-1 and PvMSP-1(19) antigens at each of the study sites. Two factors, age and malaria positivity were significantly associated with seropositivity for both the antigens PvAMA-1 and PvMSP-1(19).Conclusion: These data suggest that natural acquired antibody response is higher for PvMSP-1(19) antigen as compared to PvAMA-1 antigen in individuals living in three geographically diverse malaria endemic regions in India. PvMSP-1(19) appears to be highly immunogenic in Indian population and has great potential as a malaria vaccine candidate. The differences in immune response against vaccine candidate antigens in different endemic settings should be taken into account for development of asexual stage based P. vivax malaria vaccine, which in turn can enhance malaria control efforts.